Project Details
Abstract
The first epidemic outbreak of Enterovirus 71 (EV 71) was reported in 1998 in Taiwan and the
outbreak of EV 71 infection happens every year. Recently, Taiwan has to face the trend of
declining birth rate. Thus, development of diagnosis methods, therapeutic drugs and
preventive vaccines is a national policy for protecting our children threats by EV 71. EV 71
belongs to piconaviridae family and is a major causative agent to induce hand, foot and mouth
disease (HFMD). However, EV 71 infection can cause the severe symptoms in a minority of
children, including fatal brainstem encephalitis, polio-like paralysis, and pulmonary edema etc.
Thus, understanding the interaction between host and EV 71 may facilitate the discovery of
anti-EV 71 drugs and preventive vaccine. The main theme of this project is to develop the
immunotherapy by enhancement of anti-EV 71 immune response and/or decrease the EV 71
mediated immunopathologic effect, using the approach of adult and newborn infectious mice.
EV 71 mainly transmits by respiratory and fecal-oral transmission. Study from the Chang
Gung memorial hospital has shown that EV 71 can be detected in stool samples within 11
weeks after HFMD recovery. This result suggests that there is a defect in mucosal immunity of
neonatal gastrointestinal tract for EV71 virus clearance so that virus can shed in
gastrointestinal tract. So, we propose three specific aims as follow: (1) to establish an EV 71
infected mouse model and compare the anti-EV 71 responses between adult and newborn
mice (2) to identify and characterize what and how CD4 T subsets are involved in EV71
infection (3) to set platforms for detection the EV 71 specific CD8 T cell quality and anti-EV
71 IgA production.
In general, antiviral immunity can be divided to two types, innate and adaptive immune
responses. Most importantly, the adaptive immune response (CD4, CD8 and Ig-producing B
cells) plays as a terminator in virus clearance. Functionally, viral specific CD8 T cells and Ig
producing B cells need the help from CD4 T cells, which provide co-stimulatory signals and
cytokines. So far, several subsets of CD4 T cells have been characterized, including Th1,
Th17, Treg and Tfh subsets. In this grant, we will try to identify and characterize what and
how CD4 T subsets are involved in the anti-EV 71 immunity or EV 71-mediated
immunopathogenesis. Then, the adoptive CD4 T-cell therapy of distinct CD4 T subset may
apply to modulate the anti-EV 71 immunity or to decrease the EV 71-mediated
immunopathogenesis.
Activated CD8 T cells are heterogeneous populations; even they recognize the same
peptide. Heterogeneous CD8 T cells against the same peptide express different patterns of
cytokines, chemokines, cytotoxic enzymes, survival molecules and transcriptional factors.
According to the results of our preliminary study, functional CD8 T cells can express almost
all above indicators and clean the viruses efficiently; in contrast, exhausted CD8 T cells lost
the production of cytokines and have an impaired function to clear virus-infected cells. This
platform can be applied to determine the efficacy of therapeutic drugs and preventive
vaccines.
Project IDs
Project ID:PC10006-0137
External Project ID:NSC100-2325-B182-003
External Project ID:NSC100-2325-B182-003
| Status | Finished |
|---|---|
| Effective start/end date | 01/05/11 → 30/04/12 |
Keywords
- Enterovirus 71
- virus infected mouse model
- Immunotherapy
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.